GSA Capital Partners’s Xenon Pharmaceuticals XENE Stock Holding History

GSA Capital Partners’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-37,308	Closed	-$1.47M	–	2080
2024 Q3	$1.47M	Buy	37,308 +30,830	+476%	+$1.24M	0.11%	232
2024 Q2	$253K	Sell	6,478 -15,136	-70%	-$605K	0.02%	1361
2024 Q1	$930K	Buy	+21,614	New	+$994K	0.07%	480
2023 Q2	–	Sell	-18,562	Closed	-$664K	–	1992
2023 Q1	$664K	Buy	18,562 +4,799	+35%	+$177K	0.07%	540
2022 Q4	$543K	Buy	+13,763	New	+$501K	0.07%	553
2016 Q2	–	Sell	-13,384	Closed	-$94K	–	1946
2016 Q1	$94K	Sell	13,384 -24,407	-65%	-$175K	0.01%	1587
2015 Q4	$304K	Sell	37,791 -28,150	-43%	-$241K	0.01%	1455
2015 Q3	$545K	Buy	65,941 +32,697	+98%	+$325K	0.03%	1079
2015 Q2	$383K	Buy	33,244 +20,944	+170%	+$290K	0.01%	1490
2015 Q1	$207K	Buy	+12,300	New	+$227K	0.01%	1913

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

GSA Capital Partners's XENE Position: Q4 2024 in Review

GSA Capital Partners sold out of Xenon Pharmaceuticals (XENE) in Q4 2024, closing a stake of 37,308 shares — an estimated $1.47M sold.

GSA Capital Partners first reported a position in XENE in Q1 2015 and held it in 10 quarters. The position peaked at $1.47M in Q3 2024. 209 funds tracked by Wall St. Rank hold XENE as of Q4 2024.

GSA Capital Partners reported no remaining Xenon Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
GSA Capital Partners sold 37,308 Xenon Pharmaceuticals shares in Q4 2024, an estimated $1.47M.
GSA Capital Partners first reported a position in Xenon Pharmaceuticals in Q1 2015 and held it in 10 quarters.
GSA Capital Partners's Xenon Pharmaceuticals position peaked at $1.47M in Q3 2024.
209 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2024.

Based on GSA Capital Partners's 13F filing for Q4 2024, filed 7 Feb 2025.